osimertinib
astrazeneca
['osimertinib', 'elios']
elios study showed that re-biopsy at pd is a challenge (39%).
metamp and egfr c797s are the main targets found at pd under osimertinib in front-line. #esmo2022 
Head of pulmonology unit @pneumo_LS @CHUdeLyon
Professor of Pulmonology @UnivLyon1
Scientific head @URCOT_lyon & @IFCTlung
#liquidbiopsy~#screening~????